Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in

ASCO 2024

DREAMM-8 supports use of novel ADC in multiple myeloma

A combination incorporating the antibody–drug conjugate belantamab mafodotin significantly improves the outcomes of people with relapsed or refractory multiple myeloma.

Read more

Highlights from ASCO 2024

Highlights of the Day: Breast Cancer – Metastatic

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Official congress content from ASCO®

Highlights of the Day: Gynecologic cancer

Dr. Moroney shares his highlights of the gynecologic cancer oral abstract session at ASCO 2024, and provides context and commentary on the findings.

Official congress content from ASCO®

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Dr. Mayer takes us through the research that caught her attention in the early breast cancer oral abstract session at ASCO 2024.

Official congress content from ASCO®

Robust response to asciminib in newly diagnosed CML

Asciminib has superior efficacy and better tolerability than standard frontline TKIs in people with a new diagnosis of chronic myeloid leukemia.

Lymphadenectomy can be omitted in some ovarian cancer patients

CARACO trial suggest that lymphadenectomy can be avoided in patients with advanced ovarian cancer treated with complete cytoreductive surgery.

Perioperative chemo outplays neoadjuvant CRT in esophageal cancer

The ESOPEC trial supports the use of perioperative chemotherapy over neoadjuvant chemoradiotherapy in patients with resectable esophageal adenocarcinoma.

LAURA heralds practice change for locally advanced NSCLC

Osimertinib after chemoradiotherapy significantly improves the outcomes of patients with unresectable stage III EGFR-mutated NSCLC.

European takeaways from ASCO 2024

Video

ASCO 2024: Key data in genitourinary cancer

Prof. Axel Merseburger shares his GU cancer highlights, such as the MAST trial of metformin in prostate cancer, the SURE-01/02 trial in bladder cancer, and more.

Video

ASCO 2024: Hot topics in lung cancer

Prof. Sanjay Popat takes us through the key lung cancer studies presented at the conference, including the LAURA and CROWN trials in NSCLC and ADRIATIC in SCLC.

Oncology Update newsletters

Stay up to date with the latest advances in Oncology with our free, editorially curated, subject-specific newsletters, tailored to your practice.

Update preferences

AI chatbot helps schedule colonoscopy appointments

Artificial intelligence-based chatbot shown to increase the number of patients rebooking missed colonoscopy appointments.

T-DXd benefit for HER2-ultralow metastatic breast cancer shown

DESTINY-Breast06 results support the use of trastuzumab deruxtecan in people with previously treated HER2-ultralow metastatic breast cancer.

Nivolumab plus ipilimumab improves unresectable HCC survival

Dual immunotherapy with nivolumab plus ipilimumab improves overall survival in people with unresectable advanced hepatocellular carcinoma.

Durable responses with dostarlimab in dMMR rectal cancer

Treatment with the PD-1 inhibitor dostarlimab produces a durable relapse-free response in locally advanced rectal cancer with mismatch repair deficiencies.

ASCO24 Highlights: Advances in NSCLC (Link opens in a new window)

Official videos from the conference and expert commentary showcasing the latest evidence in NSCLC.

Supported by:
  • Janssen Biotech, Inc.
Developed by: Springer Healthcare IME
Watch here

Durvalumab new standard of care for limited-stage SCLC

Patients with limited-stage SCLC and no progression after chemoradiation derive a significant survival benefit from the use of consolidation durvalumab.

Neoadjuvant dual immunotherapy improves melanoma outcomes

NADINA trial results support the use of neoadjuvant nivolumab plus ipilimumab, followed by response-driven adjuvant therapy, in patients with stage III melanoma.

Increasing survival in people with unresectable colorectal liver metastases

A liver transplant combined with chemotherapy significantly improves survival in patients with colorectal liver metastases compared with chemotherapy alone.

Long-term DESTINY-Breast03 results confirm previous findings

Trastuzumab deruxtecan leads to clinically significant improvements in overall and progression-free survival versus trastuzumab emtansine in women with metastatic breast cancer.

5-year CROWN update shows continued benefit of lorlatinib

Long-term data show continued benefit of first-line lorlatinib versus crizotinib in patients with advanced ALK-positive NSCLC.

Adagrasib improves PFS in previously treated KRAS-mutated NSCLC

Treatment with adagrasib leads to clinically meaningful improvement in progression-free survival compared with docetaxel in patients with previously treated KRAS G12C-mutated NSCLC.

Thermal ablation as effective as surgery for small colorectal liver metastases

Thermal ablation for small colorectal liver metastases is noninferior to surgery, and could reduce the number of complications and shorten hospital stays.

Subcutaneous amivantamab noninferior to intravenous administration

Subcutaneous amivantamab plus lazertinib is noninferior to intravenous amivantamab plus lazertinib as treatment for advanced EGFR-mutated NSCLC.

Stay up to date with more from Springer Medicine

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

  • On-demand Webinar

ADCs are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Episode 9: The gut microbiome and CAR T-cell therapy

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

Prof. Marion Subklewe
Developed by: Springer Medicine

Case-based insights: Oncology and hematology

Keep your HemOnc knowledge up to date with 45 clinical cases written by renowned experts, featuring knowledge-check questions to support your learning.

Developed by: Springer Medizin
Image Credits